Back to results
US 2021/0171475 A1Published application
Compounds
AssigneeUCL Business PLC
InventorsPaul Vincent Fish, William Mahy, Nicky John Willis, Hannah Woodward, Benjamin N Atkinson, Elliott D Bayle, James Sipthorp, Edith Yvonne Jones, Yuguang Zhao, Luca Vecchia, Reinis Reinholds Ruza
Life of this patent
Estimating the term…
Abstract
A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)
Claims20
A compound of formula (I):
- where Ar is C5 heteroaryl or a C6 N-containing heteroaryl, optionally substituted by a group selected from
- a) OH, SH, NH2, OMe, SMe, NHMe, NMe2, OEt, NHCN, Me;
- b) CN, CO2H;
- c) SO2Me, SO3−Na+;
- d) CH2Q1, where Q1 is selected from OH, OMe, Cl, CN, NHCOMe, SO3H, NRN1RN2, where RN1 and RN2 are either H or Me;
- e) C2-3 alkyl substituted by OH;
- where a N-ring heteroatom may additional bear a methyl group;
- and
- X1 is CR1;
- X2 is CR2;
- X3 is CR3;
- X5 is CR5;
- two of R1, R2, R3, R4 and R5 are H, two of R1, R2, R3, R4 and R5 are Cl and one of R1, R2, R3, R4 and R5 is CF3.
10 more elements
10-20. (canceled)
22-24. (canceled)
(canceled)
1-[2,4-dichloro-3-(trifluoromethyl)phenyl]triazole (295).
Dependencies are inferred from the claim text.